NEW YORK (GenomeWeb) – Plant Bioscience Limited announced today that it has granted a worldwide, non-exclusive license to a series of RNAi-related patents to Thermo Fischer Scientific for use with its research reagents and kits.
The deal specifically covers nine US patents related to small RNA-triggered post-transcriptional gene silencing and based on the plant work of Sainsbury Laboratory researchers David Baulcombe and Andrew Hamilton.
Financial terms of the arrangement were not disclosed.
PBL, which aims to make the IP widely available, previously inked non-exclusive licensing deals with RNAi drug developers Alnylam Pharmaceuticals and Dicerna Pharmaceuticals.